European Commission vs Big Pharma, or profit vs access?
Drug Discovery World
MARCH 29, 2023
UMNs have been defined in the context of the draft as diseases where there’s a lack of good treatments, and which have a high burden 3. For rare disease drugs, a variable RDP period of five, nine, or ten years, depending on the novelty of the drug. He pointed out that Europe was the first region to approve biosimilars.
Let's personalize your content